Evidence Comparison
Both are research compounds discussed for effects on the growth-hormone axis, but they work through different signaling pathways and are not FDA-approved anti-aging treatments.
| Feature | CJC-1295 | Ipamorelin |
|---|---|---|
| Mechanism | GHRH analogue | Ghrelin-receptor agonist / GH secretagogue |
| Regulatory status | Not FDA approved | Not FDA approved |
| Evidence | Limited human research | Early human and preclinical research |
| Key point | Hormone changes do not prove clinical benefit | Hormone changes do not prove clinical benefit |
How to interpret this comparison
A comparison should not be read as a recommendation to use either compound. The more important questions are whether the product is approved for the intended use, whether controlled human evidence exists, and whether safety is understood well enough for clinical decision-making.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.